Hostname: page-component-848d4c4894-jbqgn Total loading time: 0 Render date: 2024-06-25T07:21:09.687Z Has data issue: false hasContentIssue false
  • English
  • Français

Information on Marketed Drugs for Doctors and Patients: Experience in Six European Countries

Published online by Cambridge University Press:  10 March 2009

Philip Brown ,
Peter Charlish ,
Helen Brazier  and
Michael Butterfield
Philip Brown
Affiliation:
PJB Publications Ltd.
Peter Charlish
Affiliation:
PJB Publications Ltd.
Helen Brazier
Affiliation:
PJB Publications Ltd.
Michael Butterfield
Affiliation:
PJB Publications Ltd.
Get access Rights & Permissions [Opens in a new window]

Abstract

This article describes a project that looked at the availability of information on marketed pharmaceutical products to doctors and patients in six European countries. It examines the legal status of the drug compendia published in each country and reports on the Implementation of EC Directive 92/27/EEC on labeling and packaging. A small survey showed that it is hard to compare patient information because it is difficult to obtain copies of pack inserts available in each country. However, a limited analysis revealed some differences in the content and presentation of data for doctors and patients.

Type
Special Section: The Rational Use of Therapeutic Drugs
Information
International Journal of Technology Assessment in Health Care , Volume 11 , Issue 3 , Summer 1995 , pp. 410 - 416
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Joossens, Luk.La lisibilité de l'étiquetage et des notices des medicaments. Brussels: CRIOC, 1993.Google Scholar
2.Joossens, Luk.Les notices de médicaments dans les douze pays de la Communauté européenne. Brussels: CRIOC, 1990.Google Scholar
3.Kendall, , Vivienne (comp.). Labelling and packaging for Pharmaceuticals. Richmond: PJB Publications, 1993. (EPLC pharma law report no. 5)Google Scholar
4.Patient information as part of an educational process. Pharmaceutical Medicine, 1993, 7, 253–254.Google Scholar
5.Pearl, , Simon, . PILs and the learned intermediary shield. Pharmaceutical Marketing, 1994, 5(11)52–53.Google Scholar
6.Towards safe medicines: a guide to the control of safety, quality and efficacy of human medicines in the United Kingdom. London: HMSO, 1993.Google Scholar
7.Van der Velden, M. G. J. F.Differences in labelling of adverse reactions: a comparison of datasheets in five industrialized countries [for] WHO. 10 1993.Google Scholar
8.Van der Waarde, Karel. An investigation into the suitability of the graphic presentation of patient package inserts. Thesis submitted to the University of Reading, 09 1993.Google Scholar
9.Which? Way to Health editor calls for care by communication, not rules and Move pharmacists out of their dispensaries. [Report on Drug and Therapeutics Bulletin Symposium “Talking about drug treatments: who should say what to whom?”, 10 March 1994]. Pharmaceutical Journal, 1994, 252(03 19), 410.Google Scholar